跳至主要内容
临床试验/IRCT201109067482N1
IRCT201109067482N1已完成未知

Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.

Qazvin University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
21 years 至 80 years(—)
性别
All

入选标准

  • Diabetic patients (type 2) receiving diet or monotherapy by sulphonylurea, HbA1C=7.5 and FBS=140
  • Exclusion criteria: known case of inflammatory disease such as IBD, RA, vascultis, recent infection in one month suffering from malignancy, receiving other drug that decrease CRP level .[COX inhibitor (ASA, Celecoxib ), platlete aggregation inhibitor (clopidogrel, abciximab ), lipid lowering agents (Statins, Ezetimibe, Fenofibrate, Niacin, B blockers, antioxidants (vit E), ACEIs, ARBs ,CCBs except Amlodipine, Tamoxifen], Soye isoflavon enriched food; consumption of oral estrogen that increase CRP level, hypersensitivity to Metformin or Pioglitazone, Insulin use, Corticosteroid use, Cr >1.4 mg/dl, severe abnormal liver function test, pregnancy

排除标准

  • 未提供

研究者

相似试验